青光眼治疗市场分析及预测(按规模、份额、增长、趋势)2031 年

  • Report Code : TIPRE00018828
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 150
Buy Now

Glaucoma Therapeutics Market Trends and Growth (2021-2031)

Buy Now

青光眼治疗市场规模预计将从 2022 年的 62.4 亿美元增至 2031 年的 80.2 亿美元。预计 2021-2031 年市场复合年增长率为 3.2%。新型药物输送方法和联合疗法的开发可能仍是青光眼治疗市场的主要趋势。

青光眼治疗市场分析

青光眼是一组眼部疾病,其特征是神经组织逐渐丧失,如果不及时治疗,最终会导致视力丧失。前列腺素类似物是能够通过促进眼部引流来有效降低眼压的药物之一。青光眼患病率的飙升和产品上市的增加预计将有利于青光眼治疗市场的增长。

青光眼治疗市场概况

全球人口老龄化导致青光眼发病率不断上升,为青光眼治疗市场增长创造了巨大机遇。由于老龄人口对青光眼的易感性更高,对创新疗法和管理策略的需求正在上升。此外,定期进行眼科检查对于早期发现和管理青光眼的重要性 增加了患者的参与度和对先进治疗的需求。随着医疗保健系统满足老龄人口的需求,对青光眼研究、开发和治疗机会的投资预计将在未来几年推动市场增长。

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

青光眼治疗市场:

青光眼治疗市场
  • Glaucoma Therapeutics Market
    复合年增长率(2021 - 2031 年)
    3.2%
  • 2022 年市场规模
    62.4 亿美元
  • 2031 年市场规模
    80.2 亿美元

市场动态

增长动力
  • 青光眼患病率上升推动青光眼治疗市场
未来的趋势
  • 青光眼治疗技术进步将成为青光眼治疗市场
机会
  • 主要市场参与者扩大新兴市场影响力的策略

关键人物;主力;重要一员

  • 爱尔康公司
  • 艾伯维公司
  • 博士伦公司
  • Fera Pharmaceuticals, LLC
  • 维他命公司
  • 诺华公司
  • 太阳制药工业有限公司
  • 梯瓦制药工业有限公司
  • 西娅制药公司
  • 参天制药株式会社

区域概况

Glaucoma Therapeutics Market
  • 北美
  • 欧洲
  • 亚太
  • 南美洲和中美洲
  • 中东和非洲

市场细分

Glaucoma Therapeutics Market药物类别
  • β受体阻滞剂
  • α肾上腺素能激动剂
  • 前列腺素类似物
  • 碳酸酐酶抑制剂
  • 组合药物
Glaucoma Therapeutics Market药物类别
  • β受体阻滞剂
  • α肾上腺素能激动剂
  • 前列腺素类似物
  • 碳酸酐酶抑制剂
  • 组合药物
Glaucoma Therapeutics Market分销渠道
  • 医院药房
  • 零售药店
  • 网上药店
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

青光眼治疗市场驱动因素和机遇

青光眼疾病增多 市场利好

根据青光眼研究基金会的数据,到 2022 年,全球将有约 8000 万人患青光眼。2010 年,全球有近 840 万人因原发性开角型青光眼而失明。根据青光眼研究基金会的数据,到 2040 年,这一数字预计将增加到 2200 万。预计这将在未来一段时间内增加对青光眼治疗的需求。全球人口中青光眼发病率的上升是全球青光眼治疗市场的主要驱动力。

可穿戴技术的发展——青光眼治疗定制化的机会

青光眼是导致失明的主要原因,早期发现和治疗至关重要。可穿戴青光眼诊断和治疗已成为潜在的解决方案。传统诊断技术可提供可靠的眼压数据,但 Sensimed Triggerfish 等新兴隐形眼镜可提供持续的眼压跟踪。对于治疗,药物洗脱隐形眼镜正成为一种潜在的解决方案。治疗诊断平台将诊断和治疗功能整合到一个设备中,以提供实时监控和个性化药物剂量。

青光眼治疗市场报告细分分析

有助于得出青光眼治疗市场分析的关键部分是药物类别、适应症和分销渠道。

  • 根据药物类别,青光眼治疗市场分为β受体阻滞剂、α-肾上腺素能激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物等。前列腺素类似物在 2023 年占据最大的市场份额。
  • 市场按适应症细分为开角型青光眼、闭角型青光眼和其他类型。开角型青光眼在 2023 年占据了最大的市场份额。
  • 就分销渠道而言,市场分为医院药房、零售药房和网上药房。2023 年,医院药房占据了市场主导地位。 

青光眼治疗市场份额按地区分析

青光眼治疗市场报告的地理范围主要分为五个地区:北美、亚太、欧洲、中东和非洲、南美和中美。

2022 年,近 270 万美国人患有开角型青光眼;青光眼是美国不可逆失明的主要原因。由于该地区青光眼发病率不断上升,北美在 2022 年占据了最大的份额。对新型联合疗法和微创青光眼治疗的日益青睐以及北美主要市场参与者的存在是该地区青光眼治疗市场增长的因素。

青光眼治疗市场报告范围

报告属性细节
2022 年市场规模62.4 亿美元
2031 年市场规模80.2亿美元
全球复合年增长率(2021 - 2031 年)3.2%
历史数据2021-2022
预测期2023-2031
涵盖的领域按药物类别
  • β受体阻滞剂
  • α肾上腺素能激动剂
  • 前列腺素类似物
  • 碳酸酐酶抑制剂
  • 组合药物
按药物类别
  • β受体阻滞剂
  • α肾上腺素能激动剂
  • 前列腺素类似物
  • 碳酸酐酶抑制剂
  • 组合药物
按分销渠道
  • 医院药房
  • 零售药店
  • 网上药店
覆盖地区和国家北美
  • 我们
  • 加拿大
  • 墨西哥
欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
亚太
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
南美洲和中美洲
  • 巴西
  • 阿根廷
  • 南美洲和中美洲其他地区
中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
市场领导者和主要公司简介
  • 爱尔康公司
  • 艾伯维公司
  • 博士伦公司
  • Fera Pharmaceuticals, LLC
  • 维他命公司
  • 诺华公司
  • 太阳制药工业有限公司
  • 梯瓦制药工业有限公司
  • 西娅制药公司
  • 参天制药株式会社
  • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

青光眼治疗市场新闻和最新发展

青光眼治疗市场通过收集一级和二级研究后的定性和定量数据进行评估,其中包括重要的公司出版物、协会数据和数据库。以下是青光眼治疗市场的发展列表:

  • 美国食品药品监督管理局 (FDA) 批准了 Glaukos Corporation 的新药申请 (NDA),该申请允许每只眼睛单次注射 iDose TR(曲伏前列素前房植入物)75 mcg,这是一种前列腺素类似物,用于降低眼高压 (OHT) 或开角型青光眼 (OAG) 患者的眼压 (IOP)。(来源:Glaukos Corporation,公司新闻,2023 年)
  • 爱尔康宣布收购 Aerie Pharmaceuticals, Inc. 通过此次交易,该公司收购了 Rocklatan(奈他舒地尔和拉坦前列素滴眼液)0.02%/0.005% 和 Rhopressa(奈他舒地尔滴眼液)0.02%,以及用于治疗干眼症的 3 期候选产品 AR-15512 和一系列临床和临床前眼科候选药物。Rocklatan 和 Rhopressa 是 Rho-激酶抑制剂,用于降低开角型青光眼或眼高压患者的眼压升高。此次收购预计将扩大爱尔康在青光眼、视网膜和眼表疾病领域的产品组合。(来源:爱尔康,新闻稿,2022 年)

青光眼治疗市场报告覆盖范围和交付成果

“青光眼治疗市场规模和预测(2022-2031)”报告对以下领域进行了详细的市场分析:

  • 范围内所有主要细分市场的全球、区域和国家层面的市场规模和预测
  • 市场动态,如驱动因素、限制因素和关键机遇
  • 未来主要趋势
  • 详细的 PEST 和 SWOT 分析
  • 全球和区域市场分析涵盖关键市场趋势、主要参与者、法规和最新市场发展
  • 行业格局和竞争分析,涵盖市场集中度、热点图分析、知名参与者和最新发展
  • 详细的公司简介
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which type segment dominates the glaucoma therapeutics market?

The glaucoma therapeutics market by drug class, is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023.

Who are the major players in the glaucoma therapeutics market?

The glaucoma therapeutics market majorly consists of the players, including Inoteck Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd; Takeda Pharmaceutical Company; AstraZeneca PLC; AERIE Pharmaceuticals, Inc.; and Cipla Inc.

What factors drive the glaucoma therapeutics market?

Key factors driving the glaucoma therapeutics informatics growth are the surging prevalence of glaucoma and increasing product launches.

What are glaucoma therapeutics?

Glaucoma is a group of eye disorders characterized by the gradual loss of nerve tissue that would eventually lead to vision loss if left untreated. Prostaglandin analogs are among the drugs that are highly effective in reducing eye pressure by promoting better drainage from the eye.

What was the estimated glaucoma therapeutics market size in 2023?

The glaucoma therapeutics informatics was valued at US$ 6.24 billion in 2023.

What are the growth estimates for the glaucoma therapeutics market till 2031?

The glaucoma therapeutics market is expected to be valued at US$ 8.02 billion in 2031.

The List of Companies - Glaucoma Therapeutics Market

  1. Fera Pharmaceuticals
  2. GlaxoSmithKline plc
  3. Bristol Myers Squibb
  4. Eli Lilly and Company
  5. Amgen
  6. MannKind Corporation
  7. Sangamo Therapeutics
  8. SciClone Pharmaceuticals, Inc.
  9. Critical Therapeutics, Inc.
  10. Takeda Pharmaceutical Company

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Pharmaceuticals : READ MORE..